Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Heart Disease & Cardiovascular — Weekly Report — November 2, 2026

Home/Health Insights/Heart Disease & Cardiovascular — November 2 – November 9, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Heart Disease & Cardiovascular
Updated Monday · November 16, 2026
Heart Disease & Cardiovascular · November 2 – November 9, 2026

Heart Disease & Cardiovascular
Weekly Report

This week's data 138 new clinical trials registered across 10 countries, with 8,813 trials actively recruiting patients worldwide.
Week of November 2 – November 9, 2026
  • 138 new clinical trials registered across 10 countries.
  • 8,813 trials actively recruiting patients worldwide.
  • Notable trial: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease (8200 patients).
  • 2,148 new research papers published.
  • Top cited: "The Past, Present, and Future of Cardiac Gene Therapy." (The Canadian journal of cardiology, 4 citations).
  • Drug safety: Most reported effect across tracked medications (atorvastatin, lisinopril, metoprolol, amlodipine, warfarin) was Fatigue.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · November 2 – November 9, 2026
New Trials This Week
138.
registered Nov 2–Nov 9
Recruiting Now
8,813
active trials seeking patients
Countries
10
with active trials this week
Papers Published
2,148
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · November 2 – November 9, 2026
United States
86
Poland
21
Italy
16
Bulgaria
15
Brazil
11
Canada
11
South Korea
11
Argentina
10
United Kingdom
10
Not specified
9
0 22 44 66 86
total
Fig. 02

Trials by phase

Distribution · November 2 – November 9, 2026

New clinical trials registered this week for Heart Disease & Cardiovascular. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

138 trials registered for Heart Disease & Cardiovascular. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Virtual Reality Training Dose for Arm Recovery After Stroke: Clinical and Blood Biomarker Responses Heart Disease & Cardiovascular · Kutahya Health Sciences University (NCT07919301) Other Not Yet Recruiting 72 N/A
02 Impact of a Tailored Digital Intervention on Sedentary Behaviour and Physical Health in Long-term Cardiac Rehabilitation Patients Heart Disease & Cardiovascular · University of Lisbon (NCT07910812) Other Recruiting 64 Portugal
03 Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals Heart Disease & Cardiovascular · National University Polyclinics, Singapore (NCT07922837) Other Active Not Recruiting 57 Singapore
04 Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU Heart Disease & Cardiovascular · Columbia University (NCT07917728) Other Recruiting 240 United States
05 Real-World Validation of A Minimally Disruptive Ambulatory Blood Pressure Monitoring (ABPM) Huawei Smartwatch in Malaysia Heart Disease & Cardiovascular · Sunway University (NCT07913607) Other Enrolling By Invitation 500 Malaysia
06 Submaximal Versus Maximal Isometric Tongue Training After Stroke Heart Disease & Cardiovascular · Necmettin Erbakan University (NCT07922811) Other Completed 38 Turkey (Türkiye)
07 Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling Heart Disease & Cardiovascular · Konya City Hospital (NCT07910864) Other Not Yet Recruiting 76 Turkey (Türkiye)
08 Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders Heart Disease & Cardiovascular · Research Center of Neurology, Russia (NCT07923240) Phase 4 Active Not Recruiting 30 Russia
09 SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome Heart Disease & Cardiovascular · Kaiser Permanente (NCT07910968) Other Not Yet Recruiting 1,200 United States
10 Revascularization of Immature Teeth With Our Different Scaffolds Heart Disease & Cardiovascular · Tanta University (NCT07913880) Other Completed 40 Egypt
11 31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum Heart Disease & Cardiovascular · Chinese Academy of Medical Sciences, Fuwai Hospital (NCT07912086) Other Recruiting 1,000 China
12 Team-Based Shared Decision-Making Program in Hypertension Control (Healthy Heart - BP Program) Heart Disease & Cardiovascular · Johns Hopkins University (NCT07909161) Other Not Yet Recruiting 90 N/A
13 ARTEMIS: UC-MSCs After Mechanical Thrombectomy for Acute Ischemic Stroke Heart Disease & Cardiovascular · Royan Stem Cell Technology Company (NCT07913282) Phase 1 Not Yet Recruiting 10 Iran
14 Curcumin Nano Patch and Autonomic Function in Shift-Working Healthcare Professionals Heart Disease & Cardiovascular · Taipei Medical University Shuang Ho Hospital (NCT07910279) Other Completed 51 Taiwan
15 Long-Term Performance of Kingstron X-LINK Compared With Commercial Bioprostheses Heart Disease & Cardiovascular · West China Hospital (NCT07921797) Other Completed 268 N/A
16 A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity Heart Disease & Cardiovascular · Novo Nordisk A/S (NCT07919405) Phase 3 Not Yet Recruiting 1,408 United States
17 Out-Patient Proactive Observation With Wearable-Assisted Tracking for Cardiovascular Health Management Heart Disease & Cardiovascular · China National Center for Cardiovascular Diseases (NCT07912671) Other Not Yet Recruiting 400 China
18 Advancing Cardiovascular Health Among Adolescents With Intellectual Disabilities: Co-Development of Technology Interventions to Enhance Physical Activity Heart Disease & Cardiovascular · Michigan State University (NCT07919171) Other Not Yet Recruiting 77 N/A
19 Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial Heart Disease & Cardiovascular · Chang Gung Memorial Hospital (NCT07921108) Other Recruiting 60 Taiwan
20 Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT) Heart Disease & Cardiovascular · Sir Run Run Shaw Hospital (NCT07920055) Other Not Yet Recruiting 106 China
21 The Immediate Effect of Motor Imagery on Functional Upper Limb Movement in Stroke Survivors Assessed Using Surface Electromyography and Kinematic Analysis Heart Disease & Cardiovascular · Miroslav Haltmar (NCT07912762) Other Completed 56 Czechia
22 A Study of Bimagrumab in Participants With HFpEF Heart Disease & Cardiovascular · Eli Lilly and Company (NCT07920887) Phase 2 Not Yet Recruiting 540 United States
23 The Role of Multidimensional Prognostic Index (MPI) in the Assessment of Elderly Patients underGoING Cardiac REHABilitation Heart Disease & Cardiovascular · Istituti Clinici Scientifici Maugeri SpA (NCT07921758) Other Completed 202 Italy
24 Evaluating a Digital Aid to Improve ICD Decisions Heart Disease & Cardiovascular · Stanford University (NCT07913204) Other Recruiting 600 United States
25 Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. Heart Disease & Cardiovascular · Solsius (NCT07910721) Other Recruiting 60 France
26 nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks Heart Disease & Cardiovascular · University Hospital, Geneva (NCT07923604) Other Not Yet Recruiting 25 Switzerland
27 Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein Isolation Heart Disease & Cardiovascular · St. Josefs-Hospital Wiesbaden GmbH (NCT07910370) Other Recruiting 94 Germany
28 Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme Heart Disease & Cardiovascular · Aveiro University (NCT07922486) Other Not Yet Recruiting 657 Portugal
29 ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE) Heart Disease & Cardiovascular · Advanced MedTech Solutions Pvt. Ltd. (NCT07912541) Other Not Yet Recruiting 110 N/A
30 Heart and Brain Blood Flow in Obstructive Sleep Apnea Heart Disease & Cardiovascular · Copenhagen University Hospital, Rigshospitalet (NCT07913269) Other Not Yet Recruiting 50 Denmark
31 CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS Heart Disease & Cardiovascular · Inonu University (NCT07918391) Other Not Yet Recruiting 28 N/A
32 Remote Rehabilitation in Patients With HFpEF (PATRON-HF) Heart Disease & Cardiovascular · American Heart of Poland (NCT07918209) Other Recruiting 110 Poland
33 Study of AB-110 in Healthy and Hypertensive Participants Heart Disease & Cardiovascular · Antlia Bioscience, Inc (NCT07916961) Phase 1 Not Yet Recruiting 104 New Zealand
34 Supplemental Blood Flow Restriction Training to Improve the Upper Extremity in Chronic Stroke Heart Disease & Cardiovascular · Saint Joseph's University, Philadelphia (NCT07910734) Other Completed 16 United States
35 Clinical Health Outcomes Evaluation of Terumo Aortic Hybrid Devices Heart Disease & Cardiovascular · Vascutek Ltd. (NCT07911163) Other Not Yet Recruiting 150 N/A
36 An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) Heart Disease & Cardiovascular · United Therapeutics (NCT07923526) Phase 3 Not Yet Recruiting 400 United States
37 A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease Heart Disease & Cardiovascular · Hoffmann-La Roche (NCT07918846) Phase 3 Not Yet Recruiting 8,200 N/A
38 Validation of THRIVE and CLEOS Prognostic Models in Taiwanese Patients Undergoing Stroke Thrombectomy Heart Disease & Cardiovascular · Kuang Tien General Hospital (NCT07921875) Other Completed 233 Taiwan
39 High-Tech, High-Touch Heart Disease & Cardiovascular · Touro University, California (NCT07916818) Other Completed 43 United States
40 Sarcopenia and Training Outcomes in Post-cardiac Surgery Patients Heart Disease & Cardiovascular · Universitaire Ziekenhuizen KU Leuven (NCT07908472) Other Recruiting 300 Belgium
41 Foot Drop Rehabilitation and Mobility in Chronic Stroke Heart Disease & Cardiovascular · Umm Al-Qura University (NCT07914413) Other Not Yet Recruiting 40 Saudi Arabia
42 Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage Heart Disease & Cardiovascular · Insel Gruppe AG, University Hospital Bern (NCT07923084) Other Recruiting 264 Switzerland
43 From Skull Base to Atrial Fibrillation: Reduced Jugular Foramen Volume as a Structural Correlate of Atrial Fibrillation Heart Disease & Cardiovascular · Ankara Ataturk Sanatorium Training and Research Hospital (NCT07922655) Other Completed 240 Turkey (Türkiye)
44 Multimodality Location Prediction Accuracy of Leadless Pacemaker Positioning Heart Disease & Cardiovascular · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (NCT07908927) Other Recruiting 20 United States
45 EHR Nudges: Optimizing a Clinical Decision Support System for Evidence-Based Statin Medication Prescribing to Reduce the Risk of Cardiovascular Disease Heart Disease & Cardiovascular · NYU Langone Health (NCT07914777) Other Not Yet Recruiting 7,501 United States
46 Universal Screening for Blunt Cerebrovascular Injury Heart Disease & Cardiovascular · Inova Health Care Services (NCT07919847) Other Not Yet Recruiting 5,000 United States
47 Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery Heart Disease & Cardiovascular · Peking University First Hospital (NCT07912801) Phase 4 Not Yet Recruiting 80 China
48 Smartphone Camera Measurement of Breathing-Related Heart Rate Variability Compared With ECG in Healthy Adults Heart Disease & Cardiovascular · BELL Therapeutics Inc. (NCT07922161) Other Not Yet Recruiting 36 South Korea
49 Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning Heart Disease & Cardiovascular · Affiliated Hospital of Nantong University (NCT07908303) Other Not Yet Recruiting 5,000 China
50 Notification Of High-Risk Veterans for Access to Heart Failure Prevention Heart Disease & Cardiovascular · Palo Alto Veterans Institute for Research (NCT07910084) Other Not Yet Recruiting 250 N/A
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Heart Disease & Cardiovascular. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
atorvastatin Fatigue 1,095
lisinopril Fatigue 1,504
metoprolol Fatigue 1,797
amlodipine Fatigue 2,146
warfarin Off Label Use 241

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Heart Disease & Cardiovascular. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

2,148 papers

Recently published peer-reviewed studies related to Heart Disease & Cardiovascular, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Variability of lipoprotein(a) levels in patients with acute myocardial infarction between admission, discharge, and follow-up. Simon T et al. 10.1093/eurjpc/zwag573
View abstract

AIMS: Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease. Using Lp(a) concentrations measured during stable follow-up as the reference, we aimed to assess the temporal variability of Lp(a) after acute myocardial infarction (AMI) and to explore a pragmatic strategy for Lp(a) measurement. METHODS AND RESULTS: The FRENCHIE-Lp(a) cohort enrolled consecutive adults hospitalized for AMI in 21 centres. Lp(a) mass concentration, measured at admission, hospital discharge, and 3-12 months follow-up, was analysed both as a continuous and predefined categorical variable (≤20, >20-≤50, >50-≤70, >70 mg/dL). Assuming follow-up Lp(a) as the reference, we aimed to identify the threshold values that would allow us to accurately identify patients with Lp(a) > 70mg/dL, the threshold mostly used for patient selection in phase III trials of targeted Lp(a) therapies. A cumulative threshold analysis was performed to identify the Lp(a) value below which the misclassification rate (i.e. % of patients with follow-up Lp(a) > 70 mg/dL) remained <1%. Among 1561 patients (aged 61 ± 12 years; 21.3% women), median Lp(a) was 13 mg/dL at admission and remained stable over time (median difference overtime = 0 mg/dL). However, only 68.5% of patients remained in the same Lp(a) category overtime. In patients with discharge-Lp(a) ≤37 mg/dL (72.5% of the population), only 0.97% had Lp(a) >70 mg/dL at follow-up compared to 39.9% of those with discharge-Lp(a) >37 mg/dL. CONCLUSION: Although the median Lp(a) level remained stable between admission and follow-up, one-third of AMI patients shifted within Lp(a) categories over time. Pending external validation, an exploratory two-step strategy based on Lp(a) measurement at discharge, followed by repeat testing in patients with Lp(a) >37 mg/dL, showed a misclassification rate below 1% for identifying patients potentially needing intervention. REGISTRATION: Clinical trial Number: NCT04050956.

European journal of preventive cardiology 2026 Nov 8 PubMed
02 Lipoprotein(a) and the first manifestation of cardiovascular disease: a US national real-world analysis. Ramsis M et al. 10.1093/eurjpc/zwag572 European journal of preventive cardiology 2026 Nov 8 PubMed
03 Thymectomy Extent, Immune Recovery, and Infectious Burden After Neonatal Cardiac Surgery. Rojas A et al. 10.1161/JAHA.126.055490
View abstract

BACKGROUND: Neonatal cardiac surgery frequently requires thymectomy, but the consequences of extensive thymic removal remain uncertain. METHODS: We retrospectively studied 105 neonates undergoing sternotomy (2015-2024), comparing infections and 6-month lymphocyte recovery after partial versus total thymectomy, with Firth regression adjusted for bypass duration and surgical era. Separate cohorts underwent paired plasma biomarker (n=8) and whole-blood RNA sequencing (n=4) analysis before and after thymectomy. RESULTS: Among 105 neonates, 27 underwent partial and 78 total thymectomy. Multiple infections occurred in 2 of 27 (7%) after partial and 23 of 78 (30%) after total thymectomy (P=0.02); after adjustment for bypass duration and surgical era, the association was not statistically significant (Firth-adjusted odds ratio, 2.99 [95% CI, 0.82-15.85]; P=0.10). Median lymphocyte count decreased after total but increased after partial thymectomy (change, -0.8 versus +0.9×10/μL; P=0.011). Tumor necrosis factor-α decreased in all 8 biomarker participants (unadjusted P=0.0078). RNA sequencing in 4 patients (2 partial, 2 total thymectomy) identified 835 differentially expressed genes; pre-T-cell receptor α decreased in all 4 pairs (log2 fold change, -2.50; adjusted P=6×10). CONCLUSIONS: Total thymectomy was associated with reduced 6-month lymphocyte recovery and higher unadjusted odds of multiple infections. The infection association was not statistically significant after adjustment, and few events (2 of 27 after partial thymectomy) limit precision and cannot exclude a clinically important effect; these findings are hypothesis-generating. Biomarker and transcriptomic findings are exploratory and cannot distinguish thymectomy from surgery, maturation, or postoperative recovery. Prospective studies are underway to evaluate thymic preservation and autologous reimplantation.

Journal of the American Heart Association 2026 Nov 8 PubMed
04 [The novelties of adult advanced life support and post-resuscitation therapy according to the 2025 European Resuscitation Council guidelines]. Válint A et al. 10.1556/650.2026.33739
View abstract

The European Resuscitation Council published its updated Guidelines for Resuscitation in 2025. The revised guidelines highlight advanced life support and post-resuscitation care, as well as post-resuscitation rehabilitation, as the third and fourth links in the updated Chain of Survival. In this review, we summarize the key updates and principal messages of the new guideline on advanced life support and post-resuscitation care. Although the Advanced Life Support guidelines do not represent a paradigm shift, they place a stronger emphasis on delivering high-quality, timely resuscitation. High-quality chest compressions remain the cornerstone of resuscitation, complemented by early, safe, and correctly performed defibrillation with minimal interruptions, appropriate drug administration, and prompt identification and treatment of the underlying cause of cardiac arrest. The updated guidelines also address emerging topics, including cardiopulmonary resuscitation-induced consciousness, the specific considerations for cardiac arrest occurring in closely monitored patients, and the introduction of physiology-guided resuscitation. Similarly, the post-resuscitation care guidelines introduce no major changes compared with previous recommendations. Instead, they reinforce the importance of delivering high-quality post-resuscitation care, with particular emphasis on neuroprotection. The key components of the stabilization, diagnostic, and optimization phases include an ABCDE approach to patient assessment, optimization of oxygenation, ventilation, and hemodynamic status, seizure management, prevention of fever during the first 72 hours after return of spontaneous circulation, and identification and treatment of the underlying cause of cardiac arrest. The indications for immediate coronary angiography following successful cardiopulmonary resuscitation have been further refined, and the guidelines also clarify the diagnostic approach when a non-cardiac cause of cardiac arrest is suspected. Greater emphasis is placed on multimodal neuroprognosis and post-resuscitation rehabilitation. Orv Hetil. 2026; 167(45): 1810-1824.

Orvosi hetilap 2026 Nov 8 PubMed
05 Effects of Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: Analysis of the CADENCE Study. Tedford RJ et al. 10.1161/CIRCULATIONAHA.126.083993 Circulation 2026 Nov 8 PubMed
06 [Post-resuscitation care 2025: neurological prognosis of post-cardiac arrest brain injury]. Vámos Z et al. 10.1556/650.2026.33659
View abstract

Post-cardiac arrest brain injury represents a central component of the post-resuscitation syndrome, driven not only by the initial hypoxic-ischemic insult but also by reperfusion injury after the return or start of mechanical circulation. Complex neuronal damage accounts for a substantial proportion of mortality among successfully resuscitated patients, making reliable neurological prognostication a key objective of post-resuscitation care and clinical decision-making. The 2025 European Resuscitation Council guidelines emphasize a structured, multimodal approach to neuroprognostication. Prognosis should not rely on a single parameter; instead, it requires the integrated interpretation of clinical findings, electrophysiological data, neuroimaging results, and circulating biomarkers. This strategy aims to reduce falsely pessimistic predictions, prevent premature withdrawal of life-sustaining therapy, and avoid the unnecessary prolongation of futile intensive care in cases of irreversible brain injury. In the early phase of return of spontaneous circulation, neurological assessment may be confounded by several factors, including residual sedation, neuromuscular blockade, metabolic disturbances, and cardiorespiratory instability. Therefore, accurate prognostication depends on the correction of reversible conditions and stabilization of physiological parameters before definitive conclusions are drawn. Importantly, neurological outcome assessment is inherently time-dependent, and appropriate timing is essential for safe and evidence-based decision-making. Overall, the 2025 recommendations advocate standardized, multidisciplinary, and stepwise neuroprognostication as a cornerstone of post-resuscitation management, prioritizing patient-centered care while minimizing uncertainty and supporting long-term neurological recovery whenever possible. Orv Hetil. 2026; 167(45): 1799-1809.

Orvosi hetilap 2026 Nov 8 PubMed
07 Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial. Holmen S et al. 10.1161/CIRCULATIONAHA.126.083760
View abstract

BACKGROUND: Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may attenuate the decline in kidney function, but evidence in heart transplant recipients is limited. METHODS: The DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT) trial is a multicenter, double-blind, randomized, placebo-controlled trial conducted at six heart transplant centers in Northern Europe. We randomized adult heart transplant recipients with an estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m at least one year after transplantation 1:1 to receive dapagliflozin 10 mg or matching placebo once daily. The primary endpoint was the slope of the eGFR from 2 weeks after treatment initiation to the end of the 12-month blinded treatment period. RESULTS: Between June 2022 and September 2025, we randomized 430 participants, of whom 217 were allocated to dapagliflozin and 213 were allocated to placebo. We included the 424 patients with at least one eGFR measurement after baseline in the full analysis set. Their mean age was 53 ± 14 years and 29& were women. The eGFR at baseline was 67 ± 22 mL/min/1.73 m. The median time from transplantation was 7 (3 - 13) years. Dapagliflozin improved the chronic slope of the eGFR compared with placebo. The change in the eGFR from 2 weeks to 12 months after treatment initiation was 2.0 (95% confidence interval [CI] 1.0 - 3.1) mL/min/1.73 m in the dapagliflozin group and 0.3 (95% CI -0.8 - 1.4) mL/min/1.73 m in the placebo group for a between-group difference of 1.7 (95% confidence interval 0.1 - 3.3) mL/min/1.73 m; p = 0.03. There were no unexpected safety signals and similar rates of adverse events, including infections, between groups. CONCLUSIONS: In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.

Circulation 2026 Nov 8 PubMed
08 A Potential New Therapeutic Option for Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction. Kitzman DW et al. 10.1161/CIRCULATIONAHA.126.084111 Circulation 2026 Nov 8 PubMed
09 Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial. Lewis GD et al. 10.1161/CIRCULATIONAHA.126.084009
View abstract

BACKGROUND: Iron deficiency is present in >50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ([Formula: see text]) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak [Formula: see text] in heart failure with preserved ejection fraction with iron deficiency. METHODS: This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin <100 ng/mL or <300 ng/mL with transferrin saturation <20%. Participants were enrolled between December 2021 and April 2026. Single-dose ferric derisomaltose (1000 mg; n=44) or placebo (n=21) was administered once intravenously. The primary end point was the change in peak [Formula: see text] from baseline to 12 weeks with an analysis of covariance model including terms for treatment group, baseline peak [Formula: see text], and sex. Secondary end points included changes in [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class, health status assessed by the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score, and iron biomarkers at 12 weeks. RESULTS: Among 65 randomized participants (median age, 68 years [interquartile range, 58-76 years], 72% women, transferrin saturation 16.0±7.4%, ferritin 57.8±48.9 ng/mL), 64 (98.5%) completed the study. The median baseline peak [Formula: see text] was 12.7 mL·kg·min (interquartile range, 10.6-15.8 mL·kg·min) in the FDI group and 12.2 mL·kg·min (11.6-14.6 mL·kg·min) in the placebo group. At 12 weeks, peak [Formula: see text] improved by 1.2 mL·kg·min (95% CI, 0.6-1.7) in the FDI group and was unchanged (0.1 mL·kg·min [95% CI, -0.7 to 0.9]) in the placebo group (least-squares mean difference, 1.1 mL·kg·min [95% CI, 0.2-1.9]; =0.02). [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, and New York Heart Association class also improved in the FDI compared with the placebo group (all <0.05), whereas the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score did not differ significantly between groups (FDI group, +4.4 [95% CI, -2.4 to 11.2]; =0.20). FDI increased transferrin saturation (9.4% [95% CI, 4.9%-13.9%]) and ferritin (183 ng/mL [95% CI, 128-238]) compared with the placebo group (<0.001 for both). There were no serious adverse events related to FDI administration. CONCLUSIONS: In the largest trial to date of iron repletion in heart failure with preserved ejection fraction with iron deficiency, FDI improved multiple measures of exercise capacity. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04945707.

Circulation 2026 Nov 8 PubMed
10 Recognition Requires Nomination: The People Who Make Excellence Visible. Abdelnoor A et al. 10.1161/CIRCHEARTFAILURE.126.015173 Circulation. Heart failure 2026 Nov 8 PubMed
11 Cold-Inducible RNA-Binding Protein Alleviates Hypertensive Renal Injury Through the KEAP1-NRF2 Pathway. Zhang Y et al. 10.1002/smmd.70062
View abstract

Angiotensin II (Ang II) plays crucial roles in renal dysfunction, fibrotic changes, apoptosis, and oxidative stress. CIRBP, a cold-inducible RNA-binding protein, functions to maintain cellular homeostasis. However, its role in renal damage elicited by Ang II remains unclear. Here, we investigated the mechanisms through which overexpression alleviates renal damage caused by Ang II, and deletion induces basal renal injury. Transcriptomic analysis identified the involvement of in hypertension-related renal injury. Across the animal and cell models, overexpression attenuated Ang II-induced renal dysfunction, fibrosis, apoptosis, and inflammation, whereas deficiency aggravated basal injury and increased renal susceptibility to injury. CIRBP activated the KEAP1-NRF2 antioxidant pathway to mitigate redox stress. This renoprotective effect was reversed following the application of the NRF2 inhibitor ML385, but was resumed by the NRF2 agonist RA839. Together, CIRBP modulates redox imbalance during Ang II-mediated renal damage through KEAP1-NRF2 signaling.

Smart medicine 2026 Dec PubMed
12 Association Between Time Perspective and Fear of Disease Progression in Patients with Chronic Heart Failure: A Cross-Sectional Study. Ding Y et al. 10.2147/PPA.S649584
View abstract

PURPOSE: To describe the level of fear of disease progression (FoP) in patients with chronic heart failure (CHF) and to examine whether individual dimensions of time perspective are associated with FoP. PATIENTS AND METHODS: In this single-center cross-sectional study, we surveyed a convenience sample of 254 patients treated in the cardiovascular department of a tertiary hospital in Nantong between December 2025 and August 2026. Time perspective was measured with the Chinese version of the Zimbardo Time Perspective Inventory, and FoP with the simplified Chinese version of the Fear of Progression Questionnaire-Short Form (FoP-Q-SF), whose internal consistency in this sample was low (Cronbach's α = 0.675). Associations were examined with multiple linear regression (n = 237 complete cases) and sensitivity analyses; Holm and Benjamini-Hochberg adjustments were applied across the five time perspective coefficients. RESULTS: The mean FoP-Q-SF total score was 32.54 (SD 4.77), and 130 patients (51.18%) scored 34 or higher; this threshold was derived in cancer populations and has not been validated in heart failure. A higher past negative time perspective score was associated with higher FoP (β = 0.184, P = 0.002; Holm-adjusted P = 0.008; model = 0.496), and the association was retained in all sensitivity analyses. The present fatalistic association (β = 0.128, P = 0.029) did not remain significant after multiplicity adjustment in the primary model (Holm-adjusted P = 0.116), and its adjusted significance varied with the covariate set; it is regarded as exploratory. CONCLUSION: In this single-center sample, a past negative time perspective was independently associated with greater FoP, and a present fatalistic perspective showed a weaker, exploratory association. Because of the cross-sectional design, the limited reliability of the FoP-Q-SF in this sample, and the absence of a validated cut-off in heart failure, these findings require confirmation in longitudinal studies with validated measures before any implications for intervention can be drawn.

Patient preference and adherence 2026 PubMed
13 Designing Deterministic Content for an AI Chatbot to Support Patients in Cardiovascular Self-Management: Insights from Qualitative Interviews. Fouts D et al. 10.2147/PPA.S628813
View abstract

BACKGROUND: Text message-based chatbots powered by artificial intelligence (AI) show promise for supporting self-management, a critical component of chronic cardiovascular disease care. However, limited research has examined how these chatbots should be designed to resonate with patients from different backgrounds. This study explored how text-based, AI-driven chatbot systems can be optimized to encourage self-management behaviors among Spanish and English-speaking patients. METHODS: Participants were recruited from two clinical sites including an integrated safety-net health system and a Federally Qualified Health Center: Denver Health and Salud Family Health Centers. Semi-structured interviews were conducted, and qualitative coding continued until thematic saturation was reached. Interview topics included awareness and perceptions of chatbots, reactions to a demonstrated prototype, usability, trust and credibility, privacy concerns, preferences for personalization and messaging logistics, goal setting, and anticipated engagement with the program. RESULTS: We interviewed 10 patients of whom 5 were Spanish-speaking and 5 were English-speaking. Three major themes emerged: (1) individualized and personable support, (2) a motivating and simple self-management tool, and (3) an integrated informational gateway. Participants emphasized the importance of tailoring messages to personal circumstances such as age, income, retirement status, and preferred language. A conversational, human-like tone without medical jargon was viewed favorably. Participants valued goal setting with consistent follow-up and preferred a user-friendly, engaging design. Integration with existing healthcare systems and providers was identified as essential for fostering trust and credibility. CONCLUSION: Tailoring chatbot design to users' preferences and life contexts, combined with ease of use, may enhance engagement and support behavior change. Integrating chatbots within established healthcare systems may further build trust and credibility, representing an important and underexplored design consideration.

Patient preference and adherence 2026 PubMed
14 Diagnostic Pitfall: Mixed Connective Tissue Disease-Associated Pulmonary Hypertension Presenting With Postpartum Right-Sided Heart Failure in a 21-Year-Old-Case Report. Alla SSM et al. 10.1002/ccr3.73891
View abstract

Mixed connective tissue disease is a multisystem autoimmune condition characterized by overlapping clinical and serological features related to anti-U1-RNP antibodies of at least two connective tissue diseases. It may present with myocarditis, pericarditis, pulmonary arterial hypertension, and, less commonly, heart failure. We present a 21-year-old female with bilateral foot swelling, cough, and shortness of breath 3 months after a vaginal delivery. On examination, she was hypotensive (90/70 mmHg), with an elevated jugular venous pressure, a pulmonary systolic murmur with loud P2, and a tricuspid regurgitation murmur. Bronchial breath sounds and fine crepitations were present in both lower lung fields. She was evaluated initially for suspected postpartum cardiomyopathy. Transthoracic echocardiography was suggestive of a probable moderate to severe PAH. High-resolution computed tomography showed bilateral moderate pleural effusions, honeycombing with partial atelectasis of the underlying lung, and cardiomegaly. Computed Tomography Pulmonary Angiography (CTPA) showed findings likely consistent with probable mild pulmonary hypertension. An antinuclear antibody panel was performed and was positive for anti-U1-RNP, SS-A, SS-B, and Jo-1 antibodies. She was started on Lasix 40 mg, Aldactone 25 mg, lisinopril 10 mg, and heparin. Treatment with 20 mg of prednisolone was started and gradually tapered. Her anasarca and dyspnea improved, and she was discharged with follow-up arranged with cardiology and rheumatology. Timely identification of MCTD-associated pulmonary hypertension and its cardiovascular complications is essential and allows early commencement of treatment, which further prevents the patients from developing heart failure.

Clinical case reports 2026 Nov PubMed
15 Latent Profile Subtypes of Depressive Symptoms and Associated Factors Among Elderly Patients with Chronic Heart Failure. Hu Q et al. 10.2147/JMDH.S646486
View abstract

OBJECTIVE: To identify latent subtypes of depressive symptoms and their associated factors among elderly patients with chronic heart failure (CHF), so as to provide reference for developing targeted psychological intervention strategies. METHODS: A cross-sectional survey enrolled 423 hospitalized elderly CHF patients from June 2025 to May 2026. Assessments included SDS, SAS, Family APGAR, MLHFQ and PNI. Different from conventional SDS total-score-based severity grouping, latent profile analysis (LPA) was performed based on item-level responses of the Self-Rating Depression Scale (SDS) to derive depressive symptom profiles. Univariate tests and multinomial logistic regression were used to examine variables associated with profile membership. RESULTS: Three depressive-symptom latent profiles were identified from SDS item-level data, which largely followed a mild-to-moderate-to-severe symptom gradient: mild low-symptom type (50.35%), moderate emotion-predominant type (34.52%), severe somatic-cognitive type (15.13%). NYHA class III (OR=2.444, 95% CI: 1.238-4.823) / IV (OR=4.301, 95% CI: 1.814-10.196), living alone (OR=2.887, 95% CI: 1.630-5.113), and malnutrition (OR=1.775, 95% CI: 1.022-3.082) were independently associated with membership in the moderate emotion-predominant profile. Widowhood/divorce (OR=9.226, 95% CI: 2.695-31.586), polypharmacy (≥6 drugs) (OR=5.856, 95% CI: 1.295-26.472), and severe anxiety (OR=4.911, 95% CI: 1.275-18.921) were exclusive associated factors for the severe somatic-cognitive profile. Advanced cardiac dysfunction, solitary living and family dysfunction elevated odds for both moderate and severe profiles; mild anxiety (OR=0.183, 95% CI: 0.036-0.932) and moderate quality of life (OR=0.069, 95% CI: 0.006-0.758) were associated with lower odds of belonging to the severe-symptom profile. CONCLUSION: Depressive symptoms among elderly CHF patients show obvious heterogeneity and present an overall mild-to-moderate-to-severe symptom gradient. Our findings highlight potential high-risk groups (solitary-living patients, malnourished patients, patients with severe cardiac dysfunction and poor family support). These observational results may inform future development of stratified psychological-intervention approaches, although intervention effectiveness was not evaluated in the present cross-sectional study.

Journal of multidisciplinary healthcare 2026 PubMed
16 Prescribing, Medication Adherence, and Blood Pressure Goal Achievement Among Middle-to-Older Age Adults in a Primary Care Setting. Elhiny R et al. 10.1155/ijhy/1613515
View abstract

BACKGROUND: Blood pressure (BP) control among hypertensive people remains inadequate. This study aims to assess BP goal achievement among people prescribed antihypertensives, to examine medication nonadherence, and to identify demographics associated with goal achievements and medication nonadherence in this population. METHODS: This was a cross-sectional analysis of the Mitchelstown Cohort Study Rescreen data. Goal achievement was assessed in accordance with the 2013 European guidelines, the guidelines in place during data collection. A validated, self-reported 3-item medication nonadherence questionnaire was used, with a mean score ranging from 1 (Perfect Adherence) to 5 (Perfect Nonadherence). Nonadherence was defined as mean score > 1. Multiple imputation was used to impute missing data on covariates and outcomes. A sensitivity analysis was performed to assess the consistency of results by applying the 2024 European guideline recommendations. Multivariable logistic regression analysis was used to identify the factors associated with BP goal achievements and medication nonadherence. RESULTS: Antihypertensives were prescribed to 567 participants. Based on imputed data, 63.8% of these achieved 2013 BP goal. Mean medication nonadherence score was 1.6 (SE ± 0.06), with 34.8% participants being nonadherent. Having multiple antihypertensives pills was associated with lower likelihood of achieving BP goals. In the sensitivity analysis, 38.4% achieved 2024 BP goal and in multivariable analysis, being overweight or obese was associated with not achieving the 2024 goals. CONCLUSION: The study highlights the gap between guideline BP goals and achieving these goals in real world practice. Key patient and medication factors were identified that could guide efforts to improve BP goal achievement. ClinicalTrials.gov identifier: NCT03191227.

International journal of hypertension 2026 PubMed
17 Association Between Awareness of Dietary Intake Restriction at Two Time Points and Mortality Outcomes: A Cohort Study in Japan. Nishimoto D et al. 10.1177/15598276261498205
View abstract

Our previous study identified a modest association between awareness of dietary intake restriction and all-cause mortality. However, whether repeated awareness is associated with all-cause, cardiovascular disease (CVD), and cancer mortality remained unclear. We analyzed 14,060 participants from the Japan Multi-Institutional Collaborative Cohort Study. Participants reporting energy or fat intake restriction at two points in time, approximately 5 years apart, were classified as having both-survey energy or fat awareness, respectively. Multivariable and inverse probability-weighted (IPW) Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Over approximately 7 years, 374 deaths occurred. In the IPW model (Model 2), both-survey energy awareness was associated with lower all-cause mortality (HR, 0.76; 95% CI, 0.59-0.97) and CVD mortality (0.48; 0.24-0.97), although the latter was not significant in Model 1; the cancer association was significant in Model 1 but not in Model 2. It should be noted, however, that the number of CVD deaths was extremely low (n = 63) and that, of these, only 10 occurred among individuals with both-survey energy awareness. Both-survey fat awareness was not associated with mortality. Exploratory subgroup analyses suggested inverse awareness-mortality associations. Overall, both-survey energy awareness was inversely associated with all-cause mortality, but cause-specific findings require caution.

American journal of lifestyle medicine 2026 Nov 5 PubMed
18 Renal Function, OCT-Defined Coronary Calcification and Stent Optimization in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention: A Single-Center Cross-Sectional Study. Huynh CT et al. 10.2147/VHRM.S647284
View abstract

BACKGROUND: Reduced renal function is linked to coronary calcification, which can limit stent expansion, and to contrast-associated acute kidney injury (CI-AKI). We examined renal function, optical coherence tomography (OCT)-defined calcification and OCT measures of stent optimization in a Vietnamese provincial hospital. METHODS: This prospective, single-center, cross-sectional study included consecutive patients undergoing OCT-guided percutaneous coronary intervention (December 2023 to January 2026). eGFR was calculated with the CKD-EPI 2021 equation and CI-AKI defined by KDIGO creatinine criteria. Lesion-level associations were estimated by logistic or linear regression with patient-clustered robust standard errors, before and after adjustment for age, sex, diabetes, hypertension, smoking and acute coronary syndrome. RESULTS: The cohort comprised 300 patients, 309 procedures and 356 lesions. Mean eGFR was 79.7 ± 20.7 mL/min/1.73 m and 60 procedures (19.4%) had eGFR <60. Calcification was present in 235 lesions (66.0%). Each 10 mL/min/1.73 m lower eGFR was associated with calcification in unadjusted analysis (OR 1.19; 95% CI 1.03-1.38), but not after adjustment including age (OR 1.04; 0.88-1.22), whereas age remained associated (OR 1.46 per 10 years; 1.09-1.95). Mean minimum stent area was 5.75 ± 2.26 mm and was not correlated with eGFR (=0.05; P=0.36); stent expansion ≥80% (87.4%) and procedural success (88.7%) were not associated with eGFR in crude or adjusted models. CI-AKI occurred in 8 of 206 procedures with paired creatinine (3.9%). Subgroups with eGFR <45 (22 lesions) and <30 (7 lesions) were small, and these analyses were exploratory. CONCLUSION: In this single-center cross-sectional study, the crude association between lower eGFR and OCT-defined calcification was largely explained by age. Under OCT guidance, renal function was not associated with stent optimization, and CI-AKI was infrequent. Prospective studies with larger advanced-CKD populations and a comparator arm are needed to establish whether OCT guidance offsets renal-related procedural disadvantage.

Vascular health and risk management 2026 PubMed
19 Molecular Mechanism of Aerobic Exercise Regulating YAP to Improve TAC-Induced Heart Failure. Xu C et al. 10.1007/s12265-026-10864-7
View abstract

The Yes-associated protein (YAP) pathway regulates cardiomyocyte proliferation, apoptosis, and immune homeostasis, with dual cardiac pathophysiological roles: aberrant activation worsens heart failure (HF), while targeted inhibition of YAP restores myocardial health. This study explores how aerobic exercise and Verteporfin intervention mediate YAP signaling to mitigate HF. The study uses a pressure overload-induced HF animal model to evaluate the effects of aerobic exercise, YAP inhibition, and their combination. Aerobic exercise preserved YAP abundance and suppressed phosphorylation-YAP overexpression in TAC-induced heart failure. This improves mitochondrial ultrastructure and cardiac function. YAP inhibition attenuates maladaptive remodeling by modulating macrophage polarization, downregulating M1 and upregulating M2 markers. The combination of aerobic exercise and YAP inhibition synergistically reduces fibrosis, hypertrophy, inflammation, and restores cardiac function. These findings identify YAP as a key target for exercise-mediated cardioprotection, and the potential mechanism may be through protecting mitochondrial integrity and immune homeostasis. This study offers novel insights into exercise-regulated YAP signaling as a therapeutic strategy for pressure overload-induced HF.

Journal of cardiovascular translational research 2026 Nov 7 PubMed
20 Retraction Note: Knockdown of Long Non-Coding RNA AFAP1-AS1 Promoted Viability and Suppressed Death of Cardiomyocytes in Response to I/R In Vitro and In Vivo. Chen Z et al. 10.1007/s12265-026-10868-3 Journal of cardiovascular translational research 2026 Nov 7 PubMed
21 Single-nucleus cNMF identifies a six-gene classifier predictive of atrial fibrillation recurrence. FengHong X 10.1007/s00335-026-10287-4
View abstract

Atrial fibrillation (AF) reflects intertwined immune-stromal remodeling, yet compact and generalizable diagnostic markers remain limited. Left-atrial single-nucleus RNA-seq was analyzed using SCTransform, PCA/UMAP, and lineage-aware cNMF (K = 4-8) to define transcriptional programs. Immune-related genes were filtered via ImmPort and analyzed using clusterProfiler, ReactomePA, and Enrichr. A 16-model benchmarking framework integrating stepwise GLM and LASSO identified a six-gene panel (EXT1, ATG7, PTPRC, MERTK, IRAK3, RORA). Immune infiltration was estimated using CIBERSORTx, and clinical outcomes were assessed using Andersen-Gill and Fine-Gray models. Experimental validation included RT-qPCR, siRNA-mediated knockdown, wound-healing, colony formation, and immunofluorescence assays in AF-mimicking atrial fibroblasts. Docking-guided drug screening and gene-drug interaction assays were performed to evaluate therapeutic targeting. Luciferase assays confirmed miRNA regulation. cNMF revealed lineage-restricted programs enriched in TGF-β, interferon-α, and inflammatory signaling, with macrophage and T cell activation as dominant features. The six-gene panel achieved AUROC = 0.583 (AUPRC = 0.627) with consistent external validation. RT-qPCR confirmed upregulation of all genes under AF-like conditions. Functional assays demonstrated that MERTK and IRAK3 regulate fibroblast activation, migration, proliferation, and extracellular matrix deposition, with MERTK exerting the strongest effect. Docking-guided screening identified MK-2461 as a potent inhibitor of fibrotic remodeling, significantly reducing gene expression, wound healing, and α-SMA/collagen accumulation. Lack of additive effects with MERTK knockdown indicated target dependency. hsa-miR-155-5p directly repressed all six genes. Persistent AF showed increased recurrence and progression risk. This integrative framework links immune-stromal remodeling, miRNA regulation, functional fibroblast activation, and therapeutic targeting, identifying MERTK as a key driver and actionable target in AF progression.

Mammalian genome : official journal of the International Mammalian Genome Society 2026 Nov 7 PubMed
22 Understanding left atrial pressure: basic physiology, hemodynamics, and current echocardiographic assessment. Inoue K et al. 10.1007/s10396-026-01686-w
View abstract

Left atrial pressure (LAP) is a major determinant of pulmonary congestion and a key hemodynamic parameter in patients with heart failure and atrial fibrillation. LAP has traditionally been regarded as a surrogate of left ventricular (LV) filling pressure. However, growing evidence indicates that LAP reflects integrated interactions between left atrial (LA) mechanics, LV diastolic and systolic function, and extrinsic mechanical restraints throughout the cardiac cycle. Understanding the physiological basis of the LAP waveform provides important insights into the LA booster pump, reservoir, and conduit functions, as well as LA-LV interactions. Recent advances in echocardiography have expanded the noninvasive assessment of LAP beyond conventional Doppler indices. Contemporary approaches integrate the values of transmitral flow, mitral annular velocity, pulmonary venous flow, LA volume, and LA reservoir strain to provide a more comprehensive noninvasive assessment of LAP. In particular, LA reservoir strain has emerged as a promising marker of LAP and atrial mechanics. Additionally, exercise stress echocardiography and preload stress testing can reveal occult abnormalities in LAP responses that are not apparent at rest, particularly in patients with heart failure with preserved ejection fraction. Abnormal LAP also plays a central role in the pathophysiology of atrial fibrillation, atrial remodeling, and stiff LA physiology. This review summarizes the physiological determinants of LAP, the hemodynamic significance of the LAP waveform, and contemporary echocardiographic approaches for the assessment of LAP, and the impact of extrinsic mechanical restraints on LAP, with particular emphasis on the clinical relevance of LA-LV interactions in heart failure with preserved ejection fraction and atrial fibrillation.

Journal of medical ultrasonics (2001) 2026 Nov 7 PubMed
23 Timing of Artificial Intelligence vs Human Identification of Cardiac Amyloidosis on Echocardiography. Sollee J et al. 10.1016/j.cardfail.2026.08.016 Journal of cardiac failure 2026 Nov 7 PubMed
24 Body composition in octogenarians with chronic kidney disease. Role of gender. Cigarrán Guldris S et al. 10.1016/j.nefroe.2026.501595
View abstract

INTRODUCTION: The population with chronic kidney disease (CKD) is undergoing marked ageing, and octogenarian patients represent a growing group with distinctive clinical and functional characteristics. In this context, alterations in fluid status and body composition (BC) limit the usefulness of body mass index, necessitating a more accurate assessment with bioelectrical impedance analysis (BIA). The aim of this study was to evaluate gender-related differences in body composition in octogenarian patients with CKD in a prospective observational cohort study with a 14-year longitudinal follow-up of clinical events. METHODS: A total of 724 patients were included (46.4% women), with a mean age of 84.7 years and a mean estimated glomerular filtration rate of 36.6 ml/min/1.73 m. Vectorial tetrapolar BIA was used to analyse body composition parameters, hydration status, and bioelectrical variables, while muscle strength was assessed by handgrip dynamometry. In addition, risk of progression to kidney replacement therapy, fracture risk, cardiovascular risk, and age-adjusted comorbidity were evaluated. RESULTS: The results revealed clinically relevant gender differences. Women exhibited lower comorbidity and a lower risk of initiating kidney replacement therapy, but a significantly higher risk of osteoporotic and hip fractures. From a BC perspective, women showed higher adiposity and a greater proportion of ECW, together with lower muscle mass, lower TBW and ICW, and reduced muscle strength. Men presented greater muscle mass and strength but a higher prevalence of dynapenia. Overall sarcopenia was infrequent in the cohort. CONCLUSION: These findings highlight a marked sexual dimorphism in body composition and functional status among octogenarians with CKD, with important clinical implications for risk stratification and individualized management in this population.

Nefrologia 2026 Nov 7 PubMed
25 Elevated plasma phenylacetylglutamine is independently associated with heart failure: A cross-sectional biomarker study. Lei Y et al. 10.1016/j.cca.2026.122964
View abstract

Phenylacetylglutamine (PAGln), a microbial metabolite generated from dietary phenylalanine, has emerged as a candidate mediator in cardiovascular disease, but whether it holds diagnostic value for heart failure (HF) is unclear. We designed a cross-sectional case-control study at Xiangya Hospital, enrolling 104 participants (65 stable HF patients and 39 non-HF controls), to address this question. Plasma PAGln was quantified by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Concentrations were significantly higher in the HF group than in controls (median 1.7 vs. 1.2 μM, P = 0.001). After multivariable adjustment for age, sex, body mass index, lifestyle factors, comorbidities, and low-density lipoprotein cholesterol, every 1-SD increase in log-transformed PAGln raised HF odds by 95% (odds ratio [OR] 1.95, 95% confidence interval [CI] 1.07-3.56, P = 0.030). The top tertile carried 4.57-fold greater odds than the bottom tertile (OR 4.57, 95% CI 1.08-19.45, P = 0.040). On receiver operating characteristic (ROC) analysis, PAGln achieved an area under the curve (AUC) of 0.658 (95% CI 0.551-0.764) with 46.2% sensitivity and 84.6% specificity. PAGln tracked positively with LDL-C, total cholesterol, and fasting glucose, and inversely with estimated glomerular filtration rate. Notably, the highest PAGln levels were seen in HF with reduced ejection fraction (HFrEF), with a significant difference between non-HF and HFrEF subgroups (P = 0.01). Collectively, our results indicate that elevated plasma PAGln is independently linked to HF and may reflect disease severity, supporting its potential as a complementary metabolic biomarker for HF evaluation.

Clinica chimica acta; international journal of clinical chemistry 2026 Nov 7 PubMed
26 Hepatic ChREBP Drives Cardiac Remodeling via ApoM Non-transcriptional Repression Shuang Zhang et al. 10.1161/CIRCRESAHA.125.327537 Circulation Research 2026 Scholar
27 PERFORMANCE COMPARISON OF LOGISTIC REGRESSION, RANDOM FOREST, AND XGBOOST WITH SMOTE AND HYPERPARAMETER TUNING IN THE CLASSIFICATION OF ACUTE MYOCARDIAL INFARCTION Annisa Nur Rohmah et al. 10.21831/jktm.v12i2.28433 Jurnal Kajian dan Terapan Matematika 2026 Scholar
28 Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study. J. Blais et al. 10.1371/journal.pmed.1005012 PLoS medicine 2026 Scholar
29 FGF-23, microRNA and phosphate binders intake: Is there a relationship? A. Rind et al. 10.21518/ms2026-177 Meditsinskiy sovet = Medical Council 2026 Scholar
30 The Past, Present, and Future of Cardiac Gene Therapy. R. Hajjar 10.1016/j.cjca.2026.01.035 4 citations The Canadian journal of cardiology 2026 Scholar
31 THE ROLE AND RESULTS OF THE PREGNANCY HEART TEAM: 2025 DATA FROM MASSA INTEGRATED BIRTH CENTER G. Benedetti et al. 10.1093/eurheartjsupp/suag058.059 European Heart Journal Supplements 2026 Scholar
32 Oxidative Modifications in Cardiac Mitochondrial and Ca2+ Handling Proteins in Obesity and Metabolic Syndrome: Antioxidant Alternatives. Karla Carvajal et al. 10.1007/164_2026_794 1 citation Handbook of experimental pharmacology 2026 Scholar
33 Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial. K. Jering et al. 10.1001/jamacardio.2026.2992 JAMA cardiology 2026 Scholar
34 Unlocking the Potential of Biomarkers in Varied Cardiovascular Associated Conditions with Individualized Treatment Approaches: A Comprehensive Review. Mridula Guleria et al. 10.2174/011573403x403834251204161927 1 citation Current cardiology reviews 2026 Scholar
35 Fulminant Disseminated Gonococcal Infection Complicated by Meningitis, Endocarditis, and Septic Shock in an Immunocompetent Young Woman: A Case Report Abdul Mashood Madni et al. 10.47363/jprsr/2026(6)185 Journal of Pharmaceutical Research & Reports 2026 Scholar
36 Role of Inflammation in the Development of Heart Failure After Myocardial Infarction Ya-Chao Li et al. 10.31083/RCM49888 Reviews in Cardiovascular Medicine 2026 Scholar
37 Editorial Comment: LDL-C Reduction After CABG With Low-Dose Statin Therapy: Implications for Secondary Prevention A. Niazi et al. 10.47144/phj.v59i5.4009 Pakistan Heart Journal 2026 Scholar
38 Postpartum Low-Dose Aspirin Does Not Improve Vascular Endothelial Function in Women with a History of Preeclampsia Ru-Da Lee et al. 10.1152/physiol.2026.41.s1.2297754 Physiology 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Heart Disease & Cardiovascular
  • Week: November 2 – November 9, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:16 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —